• Prevention of infectious complications after cesarean section in women with congenital heart disease and anemia 
To content

Prevention of infectious complications after cesarean section in women with congenital heart disease and anemia 

PERINATOLOGIYA I PEDIATRIYA. 2016.3(67):15-19; doi 10.15574/PP.2016.67.15 

Prevention of infectious complications after cesarean section in women with congenital heart disease and anemia 

Davydova I., Limanskaya A., Butenko L.

SI «Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine», Kyiv

Purpose — to study the effectiveness of the Grandazol (Yuria-Pharm) in the prevention of after surgical delivery infection complications in women with congenital heart disease and anemia.

Materials and methods. It was estimated the Grandazol (Yuria-Pharm) in 19 women with congenital heart defects. Grandazol patients received in 3–5 days after delivery by cesarean section intravenous once a day (500 mg of levofloxacin, Ornidazole — 1000 mg).

Results. After treatment with Grandazol pathogenic microorganisms were sown only in one case (5.2%), which required antibiotics-reserve. In 95% of cases had complete eradication of pathogens.

Conclusions. Grandazol (Yuria-Pharm) can be used for the prevention and treatment of infectious complications in women at high risk after operative delivery with the sensitivity and resistance of microorganisms to antibiotics. In the course of our investigation there were no manifestations of allergic and other adverse reactions, observed rapid healing of the wound and eradication of pathogen.

Key words: pregnancy, heart disease, anemia, cesarean section, infectious complications, prevention, Grandazol.


1. Bereznyakov IG. 2010. Novyie vozmozhnosti terapevticheskogo ispolzovaniya levofloksatsina. Zdorove Ukrainyi. 4: 42—43.

2. Bereznyakov IG. 2006. Rezistentnost k antimikrobnyim preparatam; mehanizmyi vozniknoveniya i klinicheskoe znachenie: metodicheskie rekomendatsii. Harkov: 72.

3. Scherbak IB. 2012. Rezistentnost mikroorganizmov: era antibiotikov uhodit Letu. Tekst dlya perevoda. Ukrainskyi medychnyi chasopys. 3: 16—17.

4. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 1: Safe Prevention of the Primary Cesarean Delivery. Obstetrics & Gynecology. 2014. 123: 693—711. http://dx.doi.org/10.1097/01.AOG.0000444441.04111.1d; PMid:24553167

5. Anderson VR, Perry CM. 2008. Levofloxacin. A review of its use a high-dose, short-course treatment for bacterial infection. Drugs. 68(4): 1—5.

6. Bratzler DW, Houck PM. 2004. Antimicrobial Prophylaxis for Surgery: An Advisory Statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 38: 1706—1715. http://dx.doi.org/10.1086/421095; PMid:15227616

7. Newlin C, Kuehl T, Pickrel A et al. 2015. Cesarean Section Incision Complications and Associated Risk Factors: A Quality Assurance Project. Open Journal of Obstetrics and Gynecology. 5: 789—794. http://dx.doi.org/10.4236/ojog.2015.514111

8. Morange-Saussier V, Giraudeau B, van der Mee N et al. 2006. Nasal carriage of methicillin-resistant Staphylococcus aureus in vascular surgery. Ann Vasc Surg. 20: 767—772; 880.

9. Noel GJ. 2009. A review of Levofloxacin for the treatment of bacterial infections. Clin Med Therapeutics. 1: 433—458.

10. Gao CH, Yu LS, Zeng S et al. 2014, Mar. 27. Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns. Ther Clin Risk Manag. 10: 217—227.

11. Thompson M. 2006. An audit demonstrating a reduction in MRSA infection in a specialized vascular unit resulting from a change in infection control protocol. Eur J Vasc Endovasc Surg. 31: 609—615; 879.